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PERIPHERAL NERVOUS SYSTEMS 
 
The nervous systems can initially be divided up into the central and peripheral nervous 
systems.  The central nervous system is the brain and spinal cord and drugs that modify the 
central nervous system are considered as a subject in systematic pharmacology (therapeutics) 
section.  Everything neural, other that the central nervous system, can be considered 
peripheral nervous systems.  The peripheral nervous systems can be divided into the 
autonomic (involuntary) nervous system, which is the system that performs without your 
conscious help, and the somatic or voluntary nervous system, which you can consciously 
control (Figure 7.1).  In addition the autonomic nervous system is divided into the 
sympathetic and parasympathetic nervous systems. 
 
Figure 7.1 Nervous systems (Copyright QUT, Sheila Doggrell) 
 
This eChapter sequentially considers drugs and the sympathetic nervous system, the 
parasympathetic nervous system.  The somatic nervous system is discussed in eChapter 8. 
 
7.1. Drugs and the sympathetic nervous system 
 
 7.1.1 The sympathetic nervous system 
They activity of the sympathetic nervous system is controlled by the central nervous system, 
where the nerves arise, and travel down the spinal cord.  The sympathetic nerves come out of 
the spinal cord at the thoracic-lumbar region, and there are short pre-ganglionic nerves 
(Figure 7.2).  There are two parts of the sympathetic nervous system, one part has ganglia.  In 
the first part, the preganglionic fibres release acetylcholine on to nicotinic receptor on the 
neurones at the ganglia, and these receptors are known as nicotinic neurone receptors.  
Activation of the these receptors, leads to the release of noradrenaline from the long post-
ganglionic fibres on to an adrenoceptor on an end organ, which is often cardiac or smooth 
muscle or glands. 
 
Figure 7.2 Sympathetic Nervous System (Copyright QUT, Sheila Doggrell) 
 
In the other part of the sympathetic nervous system, the acetylcholine from the preganglionic 
fibres is also released on to nicotinic neurone receptors, but these are on specialised ganglia, 
known as the adrenal medulla.  Stimulation of the NN receptors on the adrenal medulla 
initiates the secretion of adrenaline into the circulation.   
 
As discussed in eChapter 3, there are subdivisions of adrenoceptors. The receptors for 
noradrenaline and adrenaline were originally called adrenoreceptors but this has been 
shortened to adrenoceptors over the years.  As noradrenaline and adrenaline do not have 
identical responses in the body, it was decided that there must be more than one kind of 
adrenoceptors, and the receptors were divided into α- and β-adrenoceptors.  Molecular 
biology techniques have now been able to distinguish 10 subtypes of adrenoceptors.  Drugs 
that stimulate all or most of the adrenoceptor subtypes, which noradrenaline and adrenaline 
do to a certain extent, will have widespread effects, and these effects can either be beneficial 
or detrimental.  Drugs that select one adrenoceptor will have less widespread effects and, 
hopefully, less detrimental effects.  The effects mediated (functional responses) are well 
defined for α1-, α2 -, β1-, β2- and β3- adrenoceptors, and we have drugs that can mimic or 
inhibit these responses.  Functional responses are poorly defined for most subdivisions of α1- 
and α2 -, and β4-adrenoceptors, and we have few drugs that select for these subdivision.  The 
effects mediated by the adrenoceptor subtypes are discussed in the next section. 
 
7.1.2 Effects of the sympathetic nervous system 
The effects of the sympathetic nervous system are exerted on most end organs/systems.  The 
discussion of effects given here is limited to those we modify commonly with drugs, and we 
need to know these to understand how the drugs work.  On the cardiovascular system, 
activation of the sympathetic nervous system leads to the release of noradrenaline that goes 
on to stimulate the β1-adrenoceptors of the heart and the α1-adrenoceptors on the blood 
vessels (Figure 7.3). 
 
Figure 7.3 Noradrenaline on cardiovascular system 
 
Noradrenaline stimulates the β1-adrenoceptors of the sino-atrial node (pacemaker region of 
the atria) to increase the heart rate.  Noradrenaline also stimulates the β1-adrenoceptors of the 
ventricles to increase the force at which the heart beats.  This combination of increased heart 
rate and increased heart force leads to an increase in the cardiac output.  On release from the 
sympathetic nervous system, noradrenaline also stimulates the α1-adrenoceptors on the blood 
vessels.  On the veins, noradrenaline causes venoconstriction, and noradrenaline also 
constricts the arterioles in the skin and mucous membranes.  The noradrenaline β1-
adrenoceptor-induced increase in cardiac output and α1-adrenoceptor-mediated 
vasoconstriction combine to give an increase in blood pressure. 
 
Adrenaline released from the adrenal medulla part of the sympathetic nervous system also 
has effects on the cardiovascular system.  The effects of adrenaline on the cardiovascular 
system are different to those of noradrenaline, and also depend on the concentration of 
adrenaline.  Low concentrations of adrenaline stimulate α-adrenoceptors on arterioles in 
the skin and mucous membranes to cause vasoconstriction, which is similar to noradrenaline.  
But in contrast to noradrenaline, adrenaline also stimulates β2-adrenoceptors on blood vessels 
in skeletal muscle and coronary arteries to cause vasodilation.  This mix of vasodilation and 
vasoconstriction with adrenaline means there may be no effect overall on blood pressure.  
Instead, with adrenaline, there is a redistribution of blood from cutaneous vessels to heart and 
skeletal muscle.  Low concentrations of adrenaline have little effect on the heart. 
 
With higher concentrations of adrenaline, the fight or flight response is observed.  These 
responses are similar to those observed when adrenaline is being used as drug, as the higher 
concentrations of adrenaline are used as a medicine.  With the higher concentration of 
adrenaline, all of the effects observed with low concentrations of adrenaline persist and may 
intensify, plus a more pronounced effect on heart is observed.  High concentrations of 
adrenaline stimulate the cardiac β1- adrenoceptors to induce a racey heart, a high heart rate. 
 
Sympathetic nerves innervate the kidney, and when these nerves are activated, noradrenaline 
is released and acts on β1-adrenoceptors to induce the secretion of renin into the blood stream 
(Figure 7.4). Once renin has been secreted the hormones angiotensin II and aldosterone are 
formed and carried in the blood stream. 
 
Figure 7.4 Sympathetic NS and kidney (Copyright QUT, Sheila Doggrell) 
 
Angiotensin II acts on blood vessels to cause vasoconstriction.  Aldosterone acts on the 
kidney to promote salt and water retention.  Both of these hormonal effects lead to an 
increase in blood pressure. 
 
On the urinary bladder, noradrenaline acts at α1- adrenoceptors in the neck and sphincters 
to promote contraction, and contraction in these areas promotes urinary retention.   
 
On the prostate, noradrenaline acts at α1- adrenoceptors, which are the α1A-adrenoceptor 
subtype, to contract the smooth muscle in the prostrate capsule. 
 
The effects of adrenaline released from adrenal medulla include those on the lung, where the 
tracheal and bronchial smooth muscle contains β2-adrenoceptors, and adrenaline stimulates 
these to cause bronchodilation.  The bronchial glands also have β2-adrenoceptors, and 
stimulation of these receptors leads to a decrease in secretions.   
 
On the eye, adrenaline may act at β2-adrenoceptors on ciliary epithelium to increase aqueous 
humour formation. 
  
Adrenaline has some major effects on metabolism.  On the liver, adrenaline stimulates β2-
adrenoceptors to activate the enzyme glycogen phosphorylase which catalyses 
glycogenolysis, which is the breakdown of glycogen to glucose.  Also on the liver, adrenaline 
stimulates β2-adrenoceptors to promote the process of gluconeogenesis, which is the 
conversion of amino acids to glucose. 
 
These effects of noradrenaline and adrenaline can be mimicked by drugs known as 
sympathomimetics, or inhibited by antagonists at the adrenoceptors, the adrenoceptor 
antagonists. 
 
7.1.3 Sympathomimetics 
The sympathomimetic drugs can be divided into those that do not show much selectivity for 
adrenoceptors, and these include adrenaline itself, ephedrine, and dopamine.  The other 
sympathomimetics are those that show selectivity for one of the receptors, and hence only 
mimic some of the effects of the sympathetic nervous system.  Selective sympathomimetics 
include dobutamine, salbutamol and salmeterol. 
 
The most obvious way to mimic the effects of adrenaline is to use adrenaline as a medicine. 
When used as a medicine, adrenaline stimulates all types of adrenoceptors.  Adrenaline is 
used clinically for its ability to cause an α-adrenoceptor mediated vasoconstriction.  
Adrenaline is used clinically as an additive to local anaesthetic preparations, where the local 
intense vasoconstriction decreases the absorption of the local anaesthetic to help limit the 
effect of the local anaesthetic to a local area.  Without the adrenaline, the local anaesthetic 
will spread, and the action will no longer be local but spreading/widespread.  Secondly, 
adrenaline can be applied topically to bleeding surfaces, where vasoconstriction reduces the 
surface for blood loss, and hence the blood loss.  For instance, adrenaline can be applied to 
bleeding peptic ulcers during endoscopy. 
 
Adrenaline is also used clinically for its ability to cause a β1-adrenoceptor-mediated 
increase in heart rate and force.  Thus, adrenaline is used intravenously in heart block and 
cardiac arrest.   
 
Historically, adrenaline was used to cause a β2-adrenoceptor-mediated bronchodilation.  
However, when adrenaline was used to alleviate bronchial asthma, it caused tachycardia due 
to stimulation the β1-adrenoceptor of the heart, an unwanted effect in the treatment of asthma.  
What is needed in asthma is a selective β2-adrenoceptor agonist that causes bronchodilation 
without tachycardia.  Salbutamol is a selective β2-adrenoceptor agonist, and is preferred to 
adrenaline in the treatment of asthma. 
 
Adrenaline is used in the treatment of hypersensitivity reactions including anaphylaxis, 
where there is excessive vasodilation, which can lead to circulatory collapse, and excessive 
bronchoconstriction.  This excessive vasodilation is overcome by adrenaline causing an α-
adrenoceptor-mediated vasoconstriction and the excessive bronchoconstriction by a β2-
adrenoceptor-mediated bronchodilation.   
 
In addition to having widespread effects and not being after oral administration, another 
limitation to the clinical use of adrenaline is that it is a very potent medicine, and it is difficult 
to moderate its effect.  This has been overcome by developing less potent drugs such as 
ephedrine, which also have the benefit of being active after oral administration.  Ephedrine, 
also known as pseudoephedrine, is a mixed acting amine, which means it has direct and 
indirect effects at receptors.  The direct effect is that ephedrine is a weak agonist at α- and β-
adrenoceptors, and the indirect effect is that ephedrine causes the release of noradrenaline 
(Figure 7.5).    
 
 
Figure 7.5 Mechanism of action of ephedrine (Copyright QUT, Sheila Doggrell) 
 
Most of the effect of ephedrine is probably mediated by the release of small amounts of 
noradrenaline.  The noradrenaline causes an α-adrenoceptor-mediated vasoconstriction, 
which makes it useful as a nasal decongestant.  In nasal congestion (bunged up nose) there is 
intense vasodilation, which collects lots of material.  With vasoconstriction, the blood starts 
to move again and take away the collected material to clear the nose.  Ephedrine also causes a 
small amount of β2-adrenoceptor-mediated bronchodilation, which helps clear the chest.  
Thus, ephedrine is used to treat the nasal and lung congestion of the common cold. 
 
Phenylephrine is a selective α-adrenoceptor agonist, which has no effect on β-adrenoceptors.  
Like pseudoephedrine, phenylephrine causes an α-adrenoceptor-mediated vasoconstriction to 
produce a decongestant effect.  However, phenylephrine does not cause a β2-adrenoceptor-
mediated bronchodilation.  Most people prefer ephedrine over phenylephrine for the 
treatment of a cold, probably because of the β2-adrenoceptor-mediated bronchodilation.   
 
Higher concentrations of dopamine act as a mixed acting amine (ephedrine-like).  The direct 
action is being a weak agonist at α- and β- adrenoceptors, and the indirect action is releasing 
noradrenaline, with both of these actions leading to vasoconstriction.  Dopamine is used 
intravenously in the treatment of circulatory shock (collapse) to produce vasoconstriction to 
maintain circulation. 
 
Dobutamine is a selective β1-adrenoceptor agonist, which means it has a greater effect at 
β1-adrenoceptor than at other receptors.  It is used to selectively mimic the effect of the 
sympathetic nervous system on the β1-adrenoceptors of the heart.  Thus, dobutamine is used 
to increase in heart force.  Dobutamine is not active after oral administration, and is used i.v. 
in the treatment of circulatory shock to produce an increase in heart force (inotropic) 
response. 
 
The last group of sympathomimetics are the selective β2-adrenoceptor agonists such as 
salbutamol and salmeterol.  Salbutamol and salmeterol have no effect at α-adrenoceptors, 
and are selective for β2- over β1-adrenoceptors.  Salbutamol is the standard selective β2-
adrenoceptor agonist, whereas salmeterol is a long acting selective β2- adrenoceptor agonist.  
Both medicines cause a β2-adrenoceptor-mediated bronchodilation.  Inhaled salmeterol is 
used to prevent bronchial asthma, whereas inhaled salbutamol is used in an asthma attack 
to overcome an attack, and can also be used intravenously in severe asthma attacks. 
 
Adrenoceptor antagonists are used to prevent the effects of the sympathetic nervous system.  
Clinically used agents include the selective α1-adrenoceptor antagonists, doxazosin and 
tamsulosin, the non-selective β-adrenoceptor antagonists; propranolol, timolol and esmolol, 
and the selective β1-adrenoceptor antagonists; metoprolol and atenolol. 
 
 7.1.4 Selective α1-adrenoceptor antagonists 
Prazosin is a selective α1-adrenoceptor blocker.  The α1-adrenoceptor blockade with 
prazosin causes a decrease in the noradrenaline α1-adrenoceptor mediated vasoconstriction, 
which effectively gives a vasodilation, and as a result there is a decrease in blood pressure.  
Prazosin is occasionally used as 3rd/4th line treatment of hypertension.  Thus, if people have 
very high blood pressure, which is still not controlled with 2 or 3 of the standard drugs for the 
treatment hypertension, Prazosin may be added to the regimen to increase the likelihood of 
controlling blood pressure. 
 
Tamsulosin is the first example of an uroselective blocker, that is a selective α1-adrenoceptor 
blocker, which additionally shows selectivity for α1A-adrenoceptors (which are found on the 
prostate) over α1B-adrenoceptors, which are found of blood vessels.  Thus, tamsulosin has a 
greater ability to reverse noradrenaline α1A-adrenoceptor-mediated contraction of the smooth 
muscle of the prostate than to reverse noradrenaline α1B-adrenoceptor-mediated contraction 
of the blood vessels.  Tamsulosin is used in the treatment of benign prostatic hyperplasia 
where the growth of the prostrate obstructs the bladder neck, making urination difficult in 
older men.  Tamsulosin relaxes the prostate muscle to reduce the obstruction.  Tamsulosin 
also reduces the α1-adrenoceptor contraction in the neck and sphincters of the urinary 
bladder, which makes urinating easier. 
 
 7.1.5 β-adrenoceptor antagonists 
Propranolol and timolol are non-selective β-adrenoceptor antagonists. On the heart, 
noradrenaline stimulates β1-adrenoceptors to increase heart rate and force.  Propranolol 
prevents this from happening, and effectively gives a decrease in heart rate and force (Figure 
7.6). 
 
Figure 7.6 Propranolol and heart and kidney (Copyright QUT, Sheila Doggrell) 
 
On the kidney, noradrenaline stimulates β1-adrenoceptors to cause the activation of the renin-
angiotensin-aldosterone system, with angiotensin II causing vasoconstriction, and aldosterone 
causing salt and water retention (Figure 7.5).  Propranolol prevents this from happening 
effectively reducing the activity of the renin-angiotensin-aldosterone system.  As angiotensin 
II is a potent vasoconstrictor, and aldosterone promotes salt and water retention, both of 
which increase blood pressure, there removal with propranolol leads to a decrease in blood 
pressure.   
 
Overall, propranolol has two mechanisms to decrease blood pressure.  Firstly, propranolol 
acts on the heart to decrease cardiac out and, hence, to decrease blood pressure.  Secondly, 
propranolol acts on the kidney to decrease the activity of the renin-angiotensin-aldosterone 
system, and hence, to decrease blood pressure.  This suggests that β-blockers should be 
useful in the treatment of hypertension, and they are but there are a few problems with the 
β-blockers.  
 
The first problem with using non-selective β-blockers in hypertension is that they have 
adverse effects on the cardiovascular system.  Subjects with hypertension do not feel unwell, 
and are very intolerant of taking drugs that give adverse effects.  Propranolol adversely 
affects exercise.  When you exercise, there is an activation of the sympathetic nervous 
system, release of noradrenaline, and increased heart rate and force, which allows an 
increased exercise tolerance (Figure 7.7).  Propranolol inhibits this to give a decreased 
exercise capacity, which is disconcerting for exercise junkies who have become hypertensive, 
and prescribed β-blockers. 
 
Figure 7.7 Propranolol and exercise (Copyright QUT, Sheila Doggrell) 
 
Adrenaline β2-adrenoceptor mediated vasodilation is also inhibited by β-blockers.  With 
decreased vasodilation, there is decreased heat delivered to the extremities (toes and fingers), 
and these may become cold. 
 
In addition to problems because of adverse effects, non-selective β-blockers are 
contraindicated in asthma and diabetes.  On the lung, adrenaline secreted from the adrenal 
medulla, acts at the β2-adrenoceptors to relax the bronchial smooth muscle to give a 
bronchodilation.  Propranolol prevents this happening, reducing the bronchodilation to 
effectively give a bronchoconstriction.  People with normal lung function can tolerate this, 
and there is no serious effect.  In contrast, in subjects with asthma, the bronchoconstriction 
observed with propranolol can precipitate an attack of asthma.  Consequently, non-selective 
β-blockers are contraindicated in asthmatics.  Most β1-blockers are selective not specific for 
β1-adrenoceptors - they have some effects at β2-adrenoceptors.  Consequently, selective β1-
adrenoceptor antagonists are also contraindicated in asthmatics 
  
When a person becomes hypoglycaemic, this is signal for the release of adrenaline, which 
stimulates the β2-adrenoceptors of the liver to promote both the conversion of glycogen and 
of proteins to glucose to overcome the hypoglycaemia (Figure 7.8). 
 
  
 
Figure 7.8 Hypoglycaemia stimulation of glucose production (Copyright QUT, Sheila 
Doggrell) 
 
Propranolol inhibits this production of glucose, but this is not usually a problem in non-
diabetics, as there are other ways to control glucose levels.  However, when metabolism is 
compromised or being treated in diabetes, the ability of β-blockers to inhibit these 
metabolism pathways can be a problem, and the diabetic taking β-blockers can remain or 
become hypoglycaemic. 
 
The β1-selective adrenoceptor antagonist; atenolol, is selective, not specific, for β1-
adrenoceptors, and have some effects at β2-adrenoceptors.  The selective β1-blockers are 
preferred to propranolol in the treatment of hypertension, but not really for any benefits 
relating to the selectivity, more because they have less centrally-β-adrenoceptor mediated 
side effects e.g. nightmares, due to a lesser ability to get into the central nervous system than 
propranolol.  Atenolol are, like the non-selective β-blockers, contraindicated in asthmatics, 
but (unlike propranolol) can be used with caution in subjects with diabetes.  Even bisoprolol, 
which is most selective of the selective β1-adrenoceptor antagonists, is only used with 
extreme caution in people with respiratory compromise.  Bisoprolol is often used in the 
treatment of heart failure, and this is discussed in the cardiovascular eChapters. 
 
Esmolol was developed as a short acting non-selective β-adrenoceptor blocker for 
intravenous use in critically ill patients with hypertensive emergency.  In some critically ill 
patients, blood pressure fluctuates widely. Esmolol is rapidly metabolised.  In critically ill 
patients who are hypertensive, esmolol is administered by continuous intravenously to reduce 
blood pressure.  If the blood pressure suddenly dips, the esmolol infusion is stopped, and the 
β-adrenoceptor blockade is quickly removed. 
 
On the eye, adrenaline stimulates β2-adrenoceptors to promote aqueous humour formation, 
and the more aqueous humour is in the eye, the higher the pressure is in the eye.  Timolol is a 
competitive reversible antagonist at these receptors, and is used locally to prevent the 
production of aqueous humour, and decrease the pressure in the eye, making it useful in 
glaucoma, where there is an increased intraocular pressure.  Glaucoma is the leading cause of 
irreversible blindness.  It is usually associated with elevated pressure in the eye (elevated 
intraocular pressure).  This pressure leads to damage to the optic nerve (optic neuropathy), 
which in turn leads to loss of vision, starting with peripheral vision.  Timolol is a non-
selective β-blockers, which potentially has the potential to block all the β-adrenoceptors in 
the body, but by applying timolol directly to the eye, we limit its effects to a local area.  
 
The effects of the sympathetic nervous system are often opposed by the other part of the 
autonomic nervous system, the parasympathetic nervous system. 
 
 
7.2. Drugs and the parasympathetic nervous system 
 
 7.2.1 The parasympathetic nervous system 
The parasympathetic nerves emerge from the cranio-sacral region of the spinal cord, and have 
long pre-ganglionic fibres that release acetylcholine on to NN receptors at the ganglia (Figure 
14.1).  The short post-ganglionic fibre also releases acetylcholine, but this time on to 
muscarinic receptors. 
 
Figure 7.7 Parasympathetic nervous system (Copyright QUT, Sheila Doggrell) 
 
There are at least 3 types of functional muscarinic receptors in the periphery: M1- (which are 
found in the stomach), and muscarinic M2- and M3-receptors (which are found on other end 
organs and glands). 
 
7.2.2 Effects of the parasympathetic nervous system 
Many of the effects of the parasympathetic nervous system oppose those of the sympathetic 
nervous system.  For instances, on the heart, acetylcholine is released from the 
parasympathetic nervous system to act at M2 receptors on the sinoatrial node (the pacemaker 
in the atria) to slow the heart rate.  Acetylcholine also acts on the M2 receptors on the 
ventricles, but this only causes a small decrease in heart force.  The predominant effect of the 
parasympathetic nervous system on the heart is to slow the heart beat. 
 
On the lung, acetylcholine stimulates M2 and M3 receptors on trachea and bronchial smooth 
muscle to induce bronchoconstriction.  On the lung, acetylcholine also stimulates M2 and 
M3 receptors on glands, to promote the release of secretions. 
 
On the gut, acetylcholine stimulates M2 and M3 receptors to increase motility and tone.  On 
the gut, acetylcholine also stimulates M2 and M3 receptors on sphincters to cause 
relaxation.  Thirdly, on the gut, acetylcholine stimulates M2 and M3 receptors on glands to 
promote release of secretions. 
 
On the urinary bladder, acetylcholine predominantly stimulates M3-receptors on the 
detrusor muscle of the bladder (bulb part) to cause contraction (Figure 7.8).  Acetylcholine 
predominantly stimulates M3 on the trigone and sphincter muscle to cause relaxation, and 
release the urine (Figure 7.8).  Thus, the overall effect of acetylcholine on the bladder leads to 
micturition (urination). 
 
 
 
Figure 7.8 Sites of M3 receptors on bladder (Copyright QUT, Sheila Doggrell) 
 
On the eye, acetylcholine Ach stimulates M2 and M3 receptors on the sphincter muscle of the 
iris to cause miosis (constriction of pupil).  Acetylcholine also stimulates M2 and M3 
receptors on the ciliary muscle to cause contraction for near vision.  Finally, acetylcholine 
stimulates M2 and M receptors on the lacrimal glands to increase the secretion of tears. 
 
The effects of the parasympathetic nervous system can be mimicked with muscarinic agonists 
and prevented with the anti-muscarinic agents. 
 
 7.2.3 Muscarinic agonists 
The most logical way to mimic the parasympathetic nervous system is to give acetylcholine. 
Acetylcholine is not active after oral administration, and intravenous acetylcholine has 
widespread peripheral effects, some of which are beneficial and some of which are 
detrimental.  As a quaternary ammonium compound, acetylcholine does not penetrate the 
central nervous system after intravenous administration, and consequently has no central 
effects.  Acetylcholine is rapidly degraded by the enzyme pseudocholinesterase, and is found 
in the plasma, which means that acetylcholine has a very short half-life.  For all these 
reasons, acetylcholine is not suitable for clinical use. 
 
Pilocarpine is a muscarinic agonist that can be used clinically.  Pilocarpine is a naturally 
occurring cholinomimetic alkaloid, which does not have much similarity to acetylcholine in 
structure, but does selectively stimulate muscarinic receptors.  Pilocarpine is used topically.  
Pilocarpine is resistant to cholinesterases, which means they have a longer action than 
acetylcholine.  Pilocarpine is selective for muscarinic receptors, and is used to mimic 
particular effects of the parasympathetic nervous system. 
 
On the eye, acetylcholine stimulates aqueous humour outflow, and when the aqueous humour 
leaves the eye, the intraocular pressure decreases.  Pilocarpine eye drops are used in 
glaucoma to increase aqueous humour outflow, which decreases intraocular pressure and the 
damage caused by an increased intraocular pressure.  The miotic action of stimulating 
muscarinic receptors with pilocarpine also reverses the sight distortions associated with 
glaucoma. 
 
 7.2.4 Antimuscarinic agents 
The antimuscarinics agents can be used to reverse the effects of the parasympathetic nervous 
system.  There are three groups of antimuscarinics agents.  Firstly, the naturally occurring 
alkaloids such as atropine and hyoscine (which is also known as scopolamine) were the first 
antimuscarinics agents characterised.  Secondly, there are the semi-synthetic derivatives such 
as homatropine and ipratropium.  Thirdly, there are synthetic congeners such as 
darifenacin. 
 
Homatropine has a shorter duration of action than atropine, and is used when a short acting 
effect is required e.g. some eye applications.  Ipratropium is quaternized and does not cross 
the blood brain barrier or readily cross membranes, and is used when systemic absorption is 
not required e.g. nasal spray for rhinorrhoea, inhalation for bronchial effects. 
 
Atropine is active after oral administration, does not select between M receptors, and has 
widespread effects, both beneficial and detrimental.  Atropine is not commonly used 
clinically, as it will have many adverse effects.  The exception is the use of atropine for its 
ability to reverses the effect of acetylcholine to slow heart rate.  Thus, atropine is used to treat 
bradyarrhythmias (slow irregular heart rhythms), in the emergency situation, where it is 
administered intravenously. 
 
Inhalation of ipratropium provides the reversal of bronchoconstriction (bronchodilation).  
Ipratropium is used in the treatment of allergic rhinitis (as a nasal spray), and in asthma, and 
Chronic Obstructive Pulmonary Disease (COPD) by inhalation.  COPD is the combination of 
chronic bronchitis and emphysema, which is common in long term smokers.  Antimuscarinics 
in combination with β2-adrenoceptor agonists are also available for use in COPD e.g. 
ipratropium with salbutamol.  Improvement with ipratropium in COPD is relatively small, 
but it is used as there are no drugs that give major benefits in the treatment of COPD. 
 
Acetylcholine increases gut motility.  Antimuscarinic agents decrease gut motility.  Hyoscine 
is occasionally used in the treatment of the diarrhoea associated with irritable bowel 
syndrome, and as an aid to endoscopy. 
 
Functional muscarinic M receptors on the urinary bladder are M3, and this has prompted the 
search for M3 selective antagonists to use in overactive bladder, as by selecting for M3 
receptor, many detrimental effects due to blocking the other M receptors would be avoided.  
Darifenacin shows some selectivity for M3 receptors.  As a consequence, darifenacin lower 
intravesicular (bladder) pressure, increase capacity, and reduces the frequency of contraction 
of the urinary bladder.  Darifenacin is used in the treatment of overactive urinary bladder 
disease, and enuresis (bed wetting) in children.  However, the selectivity for M3 receptors 
with oxybutynin is only partial, and the oral administration of these agents is still associated 
with dry mouth and dry eyes, which are side effects due to blocking M2 receptors. 
 
Atropine blocks the effects of acetylcholine on the eye to cause mydriasis (dilation of the 
pupil) and cycloplegia (paralysis of ciliary muscle, and loss of accommodation, and this is the 
basis for the ophthalmologic uses of antimuscarinics agents.  The antimuscarinics are given 
as eye drops to promote mydriasis and cycloplegia.  The mydriasis is required for the 
examination of retina and optic nerve.  Cycloplegia is required to allow measurement of 
refractive errors.  In ophthalmology, the shorter acting antimuscarinics such as homatropine 
are preferred, as they allow the subject to recover/see more quickly.  
  
8. 
DRUGS AND SOMATIC NERVOUS SYSTEM 
Sheila A Doggrell 
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, 
Gardens Point, GPO Box 2434, QLD 4001, Australia 
Phone +61 7 38705741 Fax +61 7 31381534 Email sheila.doggrell@qut.edu.au 
Reviewer required 
Key words: somatic nervous system, skeletal muscle, anticholinesterase, neuromuscular 
blockers, competitive neuromuscular blockers, tubocurarine, mivacurium, vecuronium, 
rocuronium, depolaring neuromuscular blocker, succinylcholine, botox 
8. Drugs and the somatic nervous system 
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 8.1 The somatic nervous system 
The somatic/voluntary nervous system is distinguishable from the branches of the autonomic 
nervous system by having no ganglia.  The nerves arising from the spinal cord release 
acetylcholine onto NM, the nicotinic receptors associated with skeletal muscle (Figure 8.1). 
 
Figure 8.1 Neuromuscular junction (Copyright QUT, Sheila Doggrell) 
 
Acetylcholine receptors were initially divided on their basis of responses to nicotine and 
muscarine, into those that responded to nicotine, nicotinic receptors, and those that responded 
to muscarine, muscarinic receptors.    The NN receptors are found at the autonomic ganglia, 
adrenal medulla and within the central nervous system.  The NM receptors are found on 
skeletal muscle innervated by the somatic nervous system.  The NM receptor can be 
stimulated by increasing the concentration of acetylcholine in the synapse and inhibited by 
neuromuscular blockers. 
 
8.2 Anticholinesterases 
In order to stimulate NM receptors, anticholinesterases are used to prevent the breakdown of 
acetylcholine, and build up the concentrations of acetylcholine at the NM receptors.  This was 
discussed in eChapter 3. 
 
 8.3 Neuromuscular blockers 
There are two types of neuromuscular blockers, non-depolarizing (which are competitive 
antagonists) and depolarizing antagonists.  The non-depolarizing (competitive) antagonists 
have no effect alone, but prevent Ach binding to NM-receptors.  The first non-depolarizing 
antagonist was tubocurarine.  Tubocurarine was known as curare and was used on in arrow 
heads to immobilize animals.  Newer examples of non-depolarizing neuromuscular blockers 
include mivacurium, vecuronium, and rocuronium.  Tubocurarine is long acting, and 
difficult to fully reverse.  The long acting non-depolarizing agents have been replaced by 
intermediate (vecuronium) and short-acting neuromuscular blockers (mivacurium).  
Vecuronium and mivacurium have a clinical duration of 60-90 minutes and 12-18 minutes, 
respectively, whereas rocuronium has a rapid onset (1-2 minutes) and intermediate duration 
(30-60 minutes). 
 
The depolarizing neuromuscular blocker is succinylcholine (also known as 
suxamethonium), which initial causes depolarization/agonism with small contractions of the 
skeletal muscle.  This is followed by causing persistent depolarization, which prevents the 
activation by acetylcholine and the skeletal muscle remains flaccid (relaxed).  The effects of 
succinylcholine usually last for 5 minutes as it is rapidly metabolised by 
pseudocholinesterase.  One in 3000 people is deficient in pseudocholinesterase, and in these 
people the effects of succinylcholine lasts for 20 h, as it is slowly metabolised. 
 
The neuromuscular blockers are used to cause paralysis of skeletal muscle.  The last muscles 
to be affected are the intercostal and diaphragm muscles.  This means that there can be 
paralysis of other skeletal muscles without paralysis of respiration, which is good as paralysis 
of respiration can be deadly.  The neuromuscular blockers are quaternary N+ compounds.  As 
discussed in eChapter 1, quaternary N+ compounds are poorly absorbed after oral 
administration, and are used intravenously. 
 
The main clinical use of neuromuscular blockers is an adjuvant in surgical anaesthesia to 
cause relaxation of skeletal muscle.  The neuromuscular blockers are also used to cause 
relaxation of skeletal muscle in intensive care.  The use of neuromuscular blockers is limited 
to anaesthesiologists or other clinicians with extensive training in their use, and the choice of 
agent depends on duration of paralysis required. 
 
The neuromuscular blockers have to be given to cause relaxation of muscles in arms and legs, 
without paralysing respiration muscle.  When too much neuromuscular blocker has been 
given, it is essential to understand the interaction with anti-cholinesterases.  Non-
depolarizing/competitive reversible antagonism can be overcome by increasing the 
concentrations of acetylcholine in the synapse with an anti-cholinesterase (e.g. neostigmine).  
Ach will compete with non-depolarising agent for receptor and displace it, and thus decrease 
the effect of the antagonist.  Depolarizing antagonism cannot be overcome by increasing the 
concentrations of acetylcholine in the synapse with an anti-cholinesterase. Ach will cause 
further depolarisation and make the block worse  
 
 8.4 Botox 
Anaerobic bacterium Clostridium botulinum produces several toxins including botulinum 
toxin A (commonly known as Botox).  Botox blocks the release of acetylcholine from all 
cholinergic nerve endings.  This means that Botox inhibits the release of acetylcholine from 
the preganglionic nerves of the autonomic nervous system (both parasympathetic nervous 
system and sympathetic nervous system), from the postganglionic nerves of parasympathetic 
NS, and from the somatic nervous system.  Thus, Botox inhibits the actions of the autonomic 
and somatic nervous system.  The blockade with Botox lasts 3 to 4 months, and restoration of 
function requires nerve growth.  Botox is best known for its use in cosmetic surgery e.g. to 
remove wrinkles.  Clinically, Botox is used to treat muscle spasms in a variety of conditions 
where other agents do not work e.g. overactive bladder.  Because Botox is extremely toxic, 
miniscule amounts are used and with intramuscular administration, there is only a local 
effect.  After botox injections, there may be pain, swelling and bruising at injection site. 
 
